Efficacia e tollerabilità a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

A. La Neve; G. Boero; N. Specchio; G. De Agazio; A. De Paio; L. M. Specchio

Efficacia e tollerabilità a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

Translated title of the contribution: Long-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy

A. La Neve, G. Boero, N. Specchio, G. De Agazio, A. De Paio, L. M. Specchio

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article › peer-review

Abstract

TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.

Translated title of the contribution	Long-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy
Original language	Italian
Pages (from-to)	83-84
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	113-114
Publication status	Published - 2001

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{5ab5ce898f4a4247a0b18320061463d3,

title = "Efficacia e tollerabilit{\`a} a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente",

abstract = "TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.",

keywords = "Long-term treatment, Refractory partial epilepsy, Topiramate",

author = "{La Neve}, A. and G. Boero and N. Specchio and {De Agazio}, G. and {De Paio}, A. and Specchio, {L. M.}",

year = "2001",

language = "Italian",

pages = "83--84",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "113-114",

}

TY - JOUR

T1 - Efficacia e tollerabilità a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

AU - La Neve, A.

AU - Boero, G.

AU - Specchio, N.

AU - De Agazio, G.

AU - De Paio, A.

AU - Specchio, L. M.

PY - 2001

Y1 - 2001

N2 - TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.

AB - TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.

KW - Long-term treatment

KW - Refractory partial epilepsy

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=0035572681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035572681&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0035572681

SP - 83

EP - 84

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 113-114

ER -

Efficacia e tollerabilità a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this